 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) Director Stephanie Okey sold 17,500 shares of Crinetics Pharmaceuticals stock in a transaction dated Thursday, March 28th. The shares...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Stephanie Okey Sells 17,500 Shares

Crinetics Pharmaceuticals (CRNX) has provided an update. Crinetics Pharmaceuticals, Inc. has introduced a new Excess Deferral Plan for a select gro...

Crinetics Pharmaceuticals Launches New Deferred Compensation Plan

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) Director Stephanie Okey sold 17,500 shares of the firm's stock in a transaction on Thursday, March 28th. The shares were sold at an...

Stephanie Okey Sells 17,500 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals gains amid pitch at Sohn charity conference (update...

Crinetics Pharmaceuticals gains amid pitch at Sohn charity conference (update)

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report)s stock had its "market outperform" rating restated by equities research analysts at JMP Securities in a report released on Thursday...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Reiterated by JMP Securities

This is a signal that CRNX's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Crinetics Pharmaceuticals (CRNX, $46.71) Stochastic Oscillator left the overbought zone on March 28, 2024

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioAtla (BCAB Research Report) and Crinetics Pharmaceuticals...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals (NASDAQ:CRNX  Free Report) had its target price hoisted by JMP Securities from $60.00 to $80.00 in a research report sent to investors on Wednesday, Benzinga reports...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $80.00

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Volume (M)	538,972.00
52-Wk High	$49.58
52-Wk Low	$15.76

CRNX Crinetics Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals